Patents by Inventor Christopher N. Boddy

Christopher N. Boddy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10301659
    Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: May 28, 2019
    Assignee: National Research Council of Canada
    Inventors: Dennis M. Whitfield, Susan M. Logan, Ian C. Schoenhofen, Christopher N. Boddy, Benjamin R. Lundgren
  • Publication number: 20170145459
    Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.
    Type: Application
    Filed: November 17, 2016
    Publication date: May 25, 2017
    Applicants: National Research Council of Canada, University of Ottawa
    Inventors: Dennis M. WHITFIELD, Susan M. LOGAN, Ian C. SCHOENHOFEN, Christopher N. BODDY, Benjamin R. LUNDGREN
  • Patent number: 9512455
    Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: December 6, 2016
    Assignees: National Research Council of Canada, University of Ottawa
    Inventors: Christopher N. Boddy, Susan M. Logan, Benjamin R. Lundgren, Ian C. Schoenhofen, Dennis M. Whitfield
  • Patent number: 9243240
    Abstract: A metabolically engineered E. coli strain which produces sialic acid and a method of making said strain. In the engineered E. coli cells, the nanT (sialic acid transporter) and nanA (sialic acid adolase) genes are inactivated, and the neuC and neuB genes of sialic acid biosynthesis in Neisseria meningitidis group B are introduced and overexpressed in the nanT? nanA? E. coli cell. In addition, the glucosamine synthase gene, glmS, of E. coli is co-overexpressed with neuB and neuC.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: January 26, 2016
    Assignee: Syracuse University
    Inventors: Christopher N. Boddy, Benjamin R. Lundgren
  • Publication number: 20140356912
    Abstract: The present invention relates to the the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.
    Type: Application
    Filed: July 28, 2014
    Publication date: December 4, 2014
    Inventors: Christopher N. Boddy, Susan M. Logan, Benjamin R. Lundgren, Ian C. Schoenhofen, Dennis M. Whitfield
  • Patent number: 8841099
    Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: September 23, 2014
    Assignees: National Research Council of Canada, University of Ottawa
    Inventors: Christopher N. Boddy, Susan M. Logan, Benjamin R. Lundgren, Ian C. Schoenhofen, Dennis M. Whitfield
  • Publication number: 20140273162
    Abstract: A metabolically engineered E. coli strain which produces sialic acid and a method of making said strain. In the engineered E. coli cells, the nanT (sialic acid transporter) and nanA (sialic acid adolase) genes are inactivated, and the neuC and neuB genes of sialic acid biosynthesis in Neisseria meningitidis group B are introduced and overexpressed in the nanT? nanA? E. coli cell. In addition, the glucosamine synthase gene, glmS, of E. coli is co-overexpressed with neuB and neuC.
    Type: Application
    Filed: February 28, 2014
    Publication date: September 18, 2014
    Applicant: SYRACUSE UNIVERSITY
    Inventors: Christopher N. Boddy, Benjamin R. Lundgren
  • Patent number: 8722365
    Abstract: A metabolically engineered E. coli strain which produces sialic acid and a method of making said strain. In the engineered E. coli cells, the nanT (sialic acid transporter) and nanA (sialic acid adolase) genes are inactivated, and the neuC and neuB genes of sialic acid biosynthesis in Neisseria meningitidis group B are introduced and overexpressed in the nanT? nanA? E. coli cell. In addition, the glucosamine synthase gene, glmS, of E. coli is co-overexpressed with neuB and neuC.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: May 13, 2014
    Assignee: Syracuse University
    Inventors: Christopher N. Boddy, Benjamin R. Lundgren
  • Patent number: 8709781
    Abstract: A system and method for heterologous expression of polyketide biosynthetic pathways from streptomycetes hosts in Escherichia coli for the production and discovery of secondary metabolites. Genomic DNA from Streptomyces rimosus encoding the oxytetracycline biosynthetic pathway is inserted into the genome of the surrogate host Myxococcus xanthus. The M. xanthus transcriptional machinery recognizes and uses the streptomycetes promoter regions to express the biosynthetic enzymes. Co-expression in E. coli of S. rimosus oxytetracycline biosynthesis enzymes and M. xanthus ?54, a key piece of the M. xanthus transcriptional machinery, enables E. coli to recognize and use the promoters from the S. rimosus oxytetracycline biosynthetic pathway, facilitating production of oxytetracycline.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: April 29, 2014
    Assignee: Syracuse University
    Inventors: Christopher N. Boddy, Anthony Garza
  • Publication number: 20130196381
    Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.
    Type: Application
    Filed: April 20, 2011
    Publication date: August 1, 2013
    Applicants: UNIVERSITY OF OTTAWA, NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Christopher N. Boddy, Susan M. Logan, Benjamin R. Lundgren, Ian C. Schoenhofen, Dennis M. Whitfield
  • Publication number: 20100184038
    Abstract: A system and method for heterologous expression of polyketide biosynthetic pathways from streptomycetes hosts in Escherichia coli for the production and discovery of secondary metabolites. Genomic DNA from Streptomyces rimosus encoding the oxytetracycline biosynthetic pathway is inserted into the genome of the surrogate host Myxococcus xanthus. The M. xanthus transcriptional machinery recognizes and uses the streptomycetes promoter regions to express the biosynthetic enzymes. Co-expression in E. coli of S. rimosus oxytetracycline biosythensis enzymes and M. xanthus ?54, a key piece of the M. xanthus transcriptional machinery, enables E. coli to recognize and use the promoters from the S. rimosus oxytetracycline biosynthetic pathway, facilitating production of oxytetracycline.
    Type: Application
    Filed: September 23, 2009
    Publication date: July 22, 2010
    Applicant: SYRACUSE UNIVERSITY
    Inventors: Christopher N. Boddy, Anthony Garza
  • Publication number: 20080153133
    Abstract: A metabolically engineered E. coli strain which produces sialic acid and a method of making said strain. In the engineered E. coli cells, the nanT (sialic acid transporter) and nanA (sialic acid adolase) genes are inactivated, and the neuC and neuB genes of sialic acid biosynthesis in Neisseria meningitidis group B are introduced and overexpressed in the nanT? nanA? E. coli cell. In addition, the glucosamine synthase gene, glmS, of E. coli is co-overexpressed with neuB and neuC.
    Type: Application
    Filed: September 26, 2007
    Publication date: June 26, 2008
    Applicant: SYRACUSE UNIVERSITY
    Inventors: Christopher N. Boddy, Benjamin R. Lundgren